Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...

Elsa Mendoza has been living with the disease for years. Here's more on her battle and what it means to have Multiple ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

Fernando Mendoza prominently mentioned his mother in his Heisman Trophy acceptance speech. Here's what you should know about ...

The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...

A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.

New Swedish research finds that people with highest microplastics and PFAS levels face double the risk of multiple sclerosis ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

People typically develop multiple sclerosis between ages 20 and 40, but late-onset MS affects those 50 years and older. Your doctor can best diagnose and advise on possible treatments, such as ...